Sökresultat
Prostatacancerscreening med Stockholm3 är kostnadseffektivt och minskar antalet onödiga biopsier
…h minskar andelen onödiga biopsier jämfört med screening med nuvarande praxis PSA test. Tidigare expertgranskade studier, exempelvis STHLM3-studien där 58 000 män deltog (publicerad i The Lancet Oncology 2015), visar att Stockholm3 har betydande hälsofördelar i jämförelse med nuvarande praxis PSA-test. Bland annat minskar antalet onödiga biopsier med 50 procent (1). Samtidigt visar andra studier att Stockholm3 hittar fler fall av behandlingskrävan…
Ska du åka på ESMO i Barcelona?
…och möjlighet till anmälan, kontakta MSD Onkologi genom någon av oss: Roland Fjellström roland.fjellstrom@merck.com Johan Fransson johan.fransson@merck.com Sandra Ingel sandra.ingel@merck.com Elisabeth Le elisabeth.le@merck.com Jessica Klang jessica.klang@merck.com Markus Lindblom markus.lindblom@merck.com Väl mött önskar MSD Onkologi…
Nordic meeting about mHSPC
…T+1) WELCOME This is a meeting initiated and funded by Astellas to support education and research in the Nordics. The aim of the meeting is to connect Nordic oncologists and urologists, together with key speakers in an interactive discussion forum. FACULTY MAIN SPEAKERS Christopher Sweeney, MBBS, Medical Oncologist Tilman Todenhöfer, Prof. Dr. med, specialist in urology NORDIC FACULTY PANEL Katarina Puco, Oncologist (NO) Antti Rannikko, Urologist…
Nivolumab + cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1st line
…This interactive virtual meeting will focus on the 9ER trial with the combination of nivolumab + cabozantinib for mRCC patients in first line. It will be chaired by Petri Bono from Finland and we are happy to share that Thomas Powles and Viktor Grünwald will walk us through the data and discuss the landscape. October 12th Time: 15:30 – 17:15 For more information and registration click here…
Lynparza rekommenderad för godkännande vid BRCA-muterad metastaserad pancreascancer i EU
…n EU by CHMP for BRCA-mutated metastatic pancreatic cancer Only PARP inhibitor to demonstrate patient benefit in a Phase III trial in this setting AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gB…